Sagimet Biosciences (SGMT) presented updated data and milestone timelines for its acne drug program at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 9, 2026, reinforcing confidence in its lead compound denifanstat and second-generation oral FASN inhibitor TVB-3567.
Denifanstat, also referred to internally as DENNY, has been in development since the company filed its first investigational new drug application in 2012. Following an FDA pre-IND meeting in December 2023 and a capital raise in April 2024, Sagimet is advancing toward a U.S. launch targeted for late 2028.
Data from the China study conducted by partner Ascletis showed a 20% placebo-adjusted improvement in Investigator Global Assessment scores and a 20% placebo-adjusted reduction in lesion counts. Lesion count improvements emerged within two weeks, with clearer separation by week four. The company plans to present the totality of 52-week Ascletis data later in September 2026 at the European Academy of Dermatology and Venereology Congress.
The AURORA Phase III trial began screening in October 2024, with first-patient dosing expected in October or November of that year. The study will enroll 800 patients across 55 sites, including 450 adolescents aged 12 to 17. Patient entry criteria require a moderate-to-severe acne classification defined by an Investigator Global Assessment score of 3 or 4, at least 30 inflammatory lesions, and 30 to 100 non-inflammatory lesions. Primary endpoints—clear or almost clear skin and absolute reductions in inflammatory and non-inflammatory lesion counts—will be assessed after three months of treatment. Enrollment is expected to complete in approximately six months, with primary endpoint data anticipated in 2025.
TVB-3567, the company's next-generation oral FASN inhibitor, entered Phase II planning with a dose-ranging study expected to yield data by the end of 2025.
China regulatory approval for denifanstat is projected between late 2024 and early 2025, while a U.S. launch remains targeted for late 2028.
Sagimet CEO Dave Happel described denifanstat in Phase III for moderate-to-severe acne as "a game changer," noting the company's patent and market exclusivity extends through November 2037, incorporating pediatric exclusivity and patent term extensions. The base composition patent expires in 2032, with method patents covering acne running to 2036. TVB-3567's composition of matter is protected through 2035, with method coverage extending into the mid-to-late 2040s.
The U.S. acne market presents an addressable population of 10 million to 15 million patients with moderate-to-severe disease, drawn from an estimated 50 million total sufferers. Approximately five million are currently treated. Competing brands SEYSARA, CABTREO, and WINLEVI carry monthly pricing ranging from roughly $1,000 to $1,200, with SEYSARA noted at $1,100 to $1,200 per month. Sagimet expects gross-to-net adjustments of 40% to 50%, payer coverage reaching 25% in Year 1, 50% in Year 2, and approximately 90% by Year 4.
Sagimet carries a market capitalization of $666 million and a current ratio above 45, reflecting a cash position significantly exceeding debt.
